Back to today’s briefing

Story perspectives

Twice-Daily Radiotherapy Outperforms Immunotherapy in Lung Cancer

10/6/2025

49 4

Summary

Story summary

Atezolizumab with chemoradiation did not improve overall survival in limited-stage small cell lung cancer (LS-SCLC).
Twice-daily radiotherapy (BID) yielded 35.4 months OS versus 28.3 months with once-daily radiotherapy (QD).
Patient-reported outcomes show better quality of life and less fatigue with BID radiotherapy; compliance was high.
Further research is needed to validate BID benefits and explore radiotherapy–immunotherapy synergy.

1 of 1

Story summary

Atezolizumab with chemoradiation did not improve overall survival in limited-stage small cell lung cancer (LS-SCLC).
Twice-daily radiotherapy (BID) yielded 35.4 months OS versus 28.3 months with once-daily radiotherapy (QD).
Patient-reported outcomes show better quality of life and less fatigue with BID radiotherapy; compliance was high.
Further research is needed to validate BID benefits and explore radiotherapy–immunotherapy synergy.